Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


No 'Unicorn' High-Cost/High-Volume Drugs Expected For 2017

Executive Summary

Specialty drugs, which have been a key driver of health care spending growth in years past, are not expected to have the same impact in 2017 – mostly because there's no "unicorn" high-cost, high-volume blockbusters, like the hepatitis C virus medicines Sovaldi and Harvoni, marketed by Gilead Sciences Inc., and Viekira Pak, sold by AbbVie Inc., anticipated to enter the market next year.


Related Content

Senators Fear Viral Spread Of Gilead Pricing Strategy
Express Scripts Repatha, Praluent Deals: What It Means
CVS takes aim at PCSK9s; costs could dwarf HCV meds
It's the volume, stupid


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts